BioRestorative Therapies, Inc. (BRTX) stock
BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
$1.34−0.08 (-5.63%)
Close on Nov 17, 2026Market cap $34.14MP/E –Yield –
BioRestorative Therapies r&d expenses
Research and development expenses are spending on new products and technology.
BioRestorative Therapies's R&D Expenses for the twelve months ending Mar 31, 2026 was $9.37M, up 29.2% year over year. For fiscal 2025 it was $10.09M, up 50.5% from the year before. Over ten years it grew 17.0% a year on average. The highest annual figure on record is $10.09M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.09M | +50.5% |
| FY2024 | Dec 31, 2024 | $6.71M | +66.2% |
| FY2023 | Dec 31, 2023 | $4.03M | +14.8% |
| FY2022 | Dec 31, 2022 | $3.51M | +381.9% |
| FY2021 | Dec 31, 2021 | $729.06K | -16.9% |
| FY2020 | Dec 31, 2020 | $876.83K | -49.1% |
| FY2019 | Dec 31, 2019 | $1.72M | +13.8% |
| FY2018 | Dec 31, 2018 | $1.51M | -29.7% |
| FY2017 | Dec 31, 2017 | $2.15M | -25.4% |
| FY2016 | Dec 31, 2016 | $2.88M | +37.0% |
| FY2015 | Dec 31, 2015 | $2.11M | +47.1% |
| FY2014 | Dec 31, 2014 | $1.43M | -10.3% |
| FY2013 | Dec 31, 2013 | $1.59M | +110.6% |
| FY2012 | Dec 31, 2012 | $756.78K | +6206.5% |
| FY2011 | Dec 31, 2011 | $12.00K | +3.3% |
| FY2010 | Dec 31, 2010 | $11.62K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $1.93M | -27.2% |
| Q4 FY2025 | Dec 31, 2025 | $2.63M | +54.3% |
| Q3 FY2025 | Sep 30, 2025 | $2.59M | +78.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.23M | +53.1% |
| Q1 FY2025 | Mar 31, 2025 | $2.65M | +150.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.70M | +56.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.45M | +79.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.45M | +61.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.06M | -14.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.09M | +61.8% |
| Q3 FY2023 | Sep 30, 2023 | $809.82K | -18.1% |
| Q2 FY2023 | Jun 30, 2023 | $902.89K | -16.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.23M | +58.9% |
| Q4 FY2022 | Dec 31, 2022 | $673.62K | +307.0% |
| Q3 FY2022 | Sep 30, 2022 | $989.17K | +316.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.08M | +568.3% |
| Q1 FY2022 | Mar 31, 2022 | $775.34K | +369.2% |
| Q4 FY2021 | Dec 31, 2021 | $165.50K | -7.0% |
| Q3 FY2021 | Sep 30, 2021 | $237.41K | -5.4% |
| Q2 FY2021 | Jun 30, 2021 | $160.90K | -38.5% |
| Q1 FY2021 | Mar 31, 2021 | $165.25K | -11.3% |
| Q4 FY2020 | Dec 31, 2020 | $177.91K | -57.2% |
| Q3 FY2020 | Sep 30, 2020 | $251.04K | -38.7% |
| Q2 FY2020 | Jun 30, 2020 | $261.55K | -40.8% |
| Q1 FY2020 | Mar 31, 2020 | $186.33K | -59.0% |
| Q4 FY2019 | Dec 31, 2019 | $415.79K | +10.7% |
| Q3 FY2019 | Sep 30, 2019 | $409.82K | +14.7% |
| Q2 FY2019 | Jun 30, 2019 | $441.72K | +18.5% |
| Q1 FY2019 | Mar 31, 2019 | $455.01K | +11.8% |
| Q4 FY2018 | Dec 31, 2018 | $375.77K | +53.2% |
| Q3 FY2018 | Sep 30, 2018 | $357.44K | -27.2% |
| Q2 FY2018 | Jun 30, 2018 | $372.82K | -39.0% |
| Q1 FY2018 | Mar 31, 2018 | $407.13K | -49.5% |
| Q4 FY2017 | Dec 31, 2017 | $245.20K | -67.4% |
| Q3 FY2017 | Sep 30, 2017 | $490.65K | -25.2% |
| Q2 FY2017 | Jun 30, 2017 | $610.73K | +0.3% |
| Q1 FY2017 | Mar 31, 2017 | $805.85K | – |
| Q4 FY2016 | Dec 31, 2016 | $752.66K | – |
| Q3 FY2016 | Sep 30, 2016 | $656.17K | – |
| Q2 FY2016 | Jun 30, 2016 | $608.69K | – |
See a number that looks wrong?